Amputee, clinician, and regulator perspectives on current and prospective upper extremity prosthetic technologies

Julie Rekant, Lee E. Fisher, Michael L. Boninger, Robert A. Gaunt, Jennifer L. CollingermedRxiv 2020 · DOI

Abstract

Existing prosthetic technologies for people with upper limb amputation are being adopted at moderate rates, yet these devices are frequently abandoned. This study aimed to: 1) assess current satisfaction with upper extremity prostheses; 2) solicit feedback on design criteria for future technologies from amputees, clinicians, and regulators; and 3) identify divergent priorities among these stakeholders. Through surveys of 21 adults with limb loss, 35 clinicians, and 3 regulators, the study evaluated existing devices and a conceptual "MyoTouch" sensorimotor prosthesis. While general technology acceptance was high across all groups, amputees showed the highest willingness to adopt invasive implantable systems. Stakeholders prioritized reliability, safety, and quality of life, though regulators placed significantly more emphasis on data privacy and long-term reliability. These findings provide a roadmap for user-centered design in the next generation of prosthetic interfaces.

Introduction: The Paradox of Modern Prosthetics

Despite significant robotic and engineering advancements, the field of upper-limb prosthetics faces a persistent challenge: abandonment. Nearly 50% of users eventually stop using their devices. This suggests a fundamental disconnect between the capabilities of modern prostheses and the daily needs of users. Current commercial devices often lack "closed-loop" functionality, meaning they provide no sensory feedback and require high cognitive loads to control.

To address this, researchers are developing "sensorimotor neuroprostheses"—systems that use implanted electrodes to decode muscle signals and stimulate nerves to restore a sense of touch. However, these systems involve surgical risks and technical complexity. This study investigates whether the primary stakeholders—the users, the clinicians who prescribe them, and the regulators who approve them—share a common vision for these future technologies.

Methodology

The researchers conducted a survey-based study involving three distinct groups:

  • Amputees (n=21): A cohort with a mean of 21.6 years since limb loss, including both congenital and acquired cases.
  • Clinicians (n=35): Primarily prosthetists and occupational therapists with an average of 21.9 years of practice.
  • Regulators (n=3): Experts from the FDA involved in medical device oversight.

The study utilized the Disability of the Arm, Shoulder, and Hand (DASH) and Trinity Amputation and Prosthesis Experience Scale-Revised (TAPES-R) metrics to evaluate current satisfaction. To explore future directions, participants were presented with a conceptual system called "MyoTouch." This system features implanted myoelectric control and sensory feedback delivered via dorsal root ganglion (DRG) stimulation.

The Satisfaction Paradox

One of the study's most revealing findings is the "Satisfaction Paradox." Participants reported the highest levels of satisfaction with simple cosmetic prostheses and the lowest satisfaction with sophisticated myoelectric devices. This suggests that as the technological complexity of a device increases, so do user expectations. When high-tech devices fail to provide intuitive control or sensory feedback, the resulting frustration often leads to abandonment.

The functional need remains high; amputees in the study had a mean DASH score of 28.2%, compared to the 14% norm for healthy controls. This gap underscores the limitations of current prosthetic solutions in restoring daily function.

The Risk Tolerance Gap

A significant finding was the divergence in risk tolerance between users and professionals. Amputees reported a 75.5% acceptance rate for the invasive MyoTouch system, significantly higher than the 68.8% reported by clinicians. Amputees, particularly those suffering from residual limb pain (who showed a 79.4% acceptance rate), were far more willing to undergo surgery for the promise of better function and pain management than the clinicians who treat them.

This "perspective gap" suggests that clinicians may be more risk-averse, potentially acting as gatekeepers for advanced technologies that patients are actually eager to adopt.

Design Priorities: Reliability and Sensory Feedback

Across all stakeholder groups, sensory feedback—the ability to "feel" objects—was identified as the most desirable feature of future technology. It is viewed as the essential component for achieving true prosthetic embodiment.

However, this enthusiasm is tempered by a demand for extreme reliability. Approximately 50% of both amputees and clinicians stated that an implanted prosthesis must achieve 99% to 100% reliability to be acceptable for daily use. There is little patience for "glitchy" technology when it is physically integrated into the body.

The Regulator’s Lens: Privacy and Safety

While amputees and clinicians focused on function and reliability, the three regulators provided a unique perspective on systemic risks. Two-thirds of the regulators identified data privacy as a critical concern—a factor that was largely ignored by the other groups. Regulators also emphasized the need for "meaningful benefit" and long-term safety evidence, prioritizing these over raw technical performance.

Differences also emerged regarding battery life. While 65% of amputees were satisfied with 8 hours of battery life (enough for a standard workday), clinicians and regulators advocated for a full day or more to ensure safety and utility in varied environments.

Conclusion and Future Directions

The successful integration of neuroprosthetics into clinical practice requires bridging the gaps between user desire, clinical caution, and regulatory oversight. The high acceptance of invasive technology among amputees suggests a strong appetite for innovation, provided it delivers on the promise of sensory feedback and high reliability.

Future clinical trial protocols should incorporate shared decision-making models to ensure that clinician risk-aversion does not unnecessarily limit patient access to transformative technologies. By aligning design criteria with the priorities of all stakeholders—prioritizing reliability, sensory restoration, and user-centered outcomes—the field can move closer to reducing abandonment and improving the lives of those with upper limb loss.

Summary updated

Abstract

Existing prosthetic technologies for people with upper limb amputation are being adopted at moderate rates and unfortunately these devices are often abandoned. The aims of this study were to: 1) understand the current state of satisfaction with upper extremity prostheses, 2) solicit feedback about prosthetic technology and important device design criteria from amputees, clinicians, and device regulators, and 3) compare and contrast these perspectives to identify common or divergent priorities. Twenty-one adults with upper limb loss, 35 clinicians, and 3 regulators completed a survey on existing prosthetic technologies and a conceptual sensorimotor prosthesis driven by implanted myoelectric electrodes with sensory feedback provided via stimulation of dorsal root ganglion. User and clinician ratings of satisfaction with existing prosthetic devices were similar. While amputees, clinicians, and regulators were similarly accepting of technology in general, amputees were most accepting of the proposed implantable sensorimotor prosthesis. Overall, stakeholders valued user-centred outcomes such as individualized task goals, improved quality of life, device reliability, and user safety; a large emphasis was put on these last two outcomes by regulators. The results of this study provide insight into the priorities of amputees, clinicians, and regulators that will inform future upper-limb prosthetic design and clinical trial protocol development.
BibTeX
@misc{rekant2020amputee,
  author = {Julie Rekant and Lee E. Fisher and Michael L. Boninger and Robert A. Gaunt and Jennifer L. Collinger},
  title = {{Amputee, clinician, and regulator perspectives on current and prospective upper extremity prosthetic technologies}},
  year = {2020},
  doi = {10.1101/2020.08.07.20170209},
  howpublished = {medRxiv},
}
Figure